ArticleESMO real world data and digital oncology2026
Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.
Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). However, treatment resistance and progression remain significant challenges, and optimal second-line strategies are not well defined. Materials and methods: HERMIONE-13 is a multicentre, observational study conducted across 18 Italian centres, including both retrospective and prospective cohorts. The study aimed to describe real-world second-line treatment patterns following progression on CDK4/6i and to identify factors influencing therapeutic decisions. Clinical outcomes, including real-world progression-free survival (rwPFS) and overall survival (OS), were also evaluated. Results: Among 254 assessable patients, 67.3% received chemotherapy (CHT) and 32.7% received ET ± targeted therapy (TT) as second-line treatment. The most common regimens included capecitabine and everolimus plus exemestane. Multivariable analysis showed that younger age, prior fulvestrant use, and shorter CDK4/6i duration were associated with CHT choice. Median rwPFS was 5.8 months for CHT and 5.3 months for ET ± TT. Median OS was longer in the ET ± TT group (3.8 versus 2.3 years). Metronomic CHT showed promising activity with a median rwPFS of 9.7 months. Conclusions: In the Italian real-world setting, CHT remains the predominant second-line choice after CDK4/6i failure, though ET ± TT may offer comparable or superior outcomes in selected patients. Treatment decisions are influenced by clinical history and patient characteristics. These findings underscore the need for personalized approaches and molecular profiling to guide post-CDK4/6i therapy in HR-positive/HER2-negative MBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.